Skip to main navigation

Top

Skip to main content

About Us

About Us
Rare Diseases

Rare Defined Diseases
Pipeline

Pipeline
Our Medicine

Our Medicine
Patients & Partners

Patients & Partners
Investors

Investors
Inside Agios

Inside Agios

Press Releases

Investors Overview
News & Events
Stock Information
Corporate Governance
Financials
IR Resources

Year

Sep 05, 2024

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Read More

PDF Version

Aug 06, 2024

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Read More

PDF Version

Aug 01, 2024

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Read More

PDF Version

Aug 01, 2024

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Read More

PDF Version

Jul 18, 2024

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Read More

PDF Version

Jun 15, 2024

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Read More

PDF Version

Jun 06, 2024

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET

Read More

PDF Version

Jun 03, 2024

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Read More

PDF Version

May 30, 2024

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Read More

PDF Version

May 28, 2024

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

Read More

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 23

Latest Earnings Call View Replay
Latest Form 10-K View PDF
Email Alerts Sign Up
Corporate Fact Sheet View PDF
Corporate Responsibility View PDF

Connect with us on LinkedIn or follow us on Twitter as we push forward into changing the landscape for people with rare diseases.

Connect on LinkedIn

Follow us our Twitter

Contact
About Us
Partner Opportunities
Careers

Agios Pharmaceuticals, Inc. © 2024

All right reserved.

Cookies Preferences
Copyright Info
Compliance
Sitemap
Privacy Notice
Terms of Use